Segall Bryant & Hamill LLC Lowers Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Segall Bryant & Hamill LLC lessened its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 3.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 156,056 shares of the company's stock after selling 6,376 shares during the period. Segall Bryant & Hamill LLC owned 0.14% of Vaxcyte worth $17,833,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company's stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the last quarter. RA Capital Management L.P. lifted its holdings in shares of Vaxcyte by 4.0% during the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company's stock worth $560,398,000 after purchasing an additional 312,500 shares during the period. Janus Henderson Group PLC grew its position in Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company's stock valued at $524,117,000 after buying an additional 692,492 shares during the last quarter. Capital Research Global Investors increased its stake in Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company's stock valued at $282,839,000 after buying an additional 700,414 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in Vaxcyte by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock worth $216,966,000 after buying an additional 498,359 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Vaxcyte

In related news, CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the transaction, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. The trade was a 1.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the sale, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,479,005.02. This trade represents a 8.13 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 117,464 shares of company stock valued at $12,640,276 in the last 90 days. 3.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

PCVX has been the topic of several analyst reports. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Leerink Partners raised their price target on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a report on Tuesday, September 3rd. Finally, Jefferies Financial Group upped their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of "Buy" and an average target price of $147.50.

Vaxcyte Trading Down 1.3 %

PCVX stock opened at $85.96 on Thursday. The firm has a 50 day moving average of $108.95 and a 200-day moving average of $89.11. Vaxcyte, Inc. has a 12-month low of $48.24 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period last year, the firm earned ($0.91) EPS. Sell-side analysts forecast that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.